Fox A W, Yang X, Murli H, Lawlor T E, Cifone M A, Reno F E
Cypros Pharmaceutical Corporation, Carlsbad, California 92008, USA.
Fundam Appl Toxicol. 1996 Jul;32(1):87-95. doi: 10.1006/faat.1996.0110.
Sodium dichloroacetate (DCA) is a drug with potential for treating patients with stroke and head injury. Conflicting evidence has been published on the mutagenic potential of DCA. A series of genetic tests for mutagenicity and clastogenicity was carried out on pharmaceutical grade DCA. Four types of mutagenicity test were included, with and without metabolic activation where appropriate. These studies included: (i) Salmonella and Escherichia coli mutation (Ames) test, (ii) thymidine kinase locus forward mutation in L5178Y mouse lymphoma cells, (iii) tests for chromosomal aberrations in Chinese hamster ovary cells, and (iv) and in vivo rat bone marrow erythroid micronucleus test. In each study, there was no evidence of mutagenic activity attributable to DCA. It is possible that the present test material, of pharmaceutical grade, has fewer impurities than materials studied in previous reports. These data extend, and in some cases contradict, previous published reports on DCA.
二氯醋酸钠（DCA）是一种有潜力治疗中风和头部受伤患者的药物。关于DCA的致突变潜力已发表了相互矛盾的证据。对药用级DCA进行了一系列致突变性和染色体断裂作用的基因检测。包括四种类型的致突变性检测，适当时有或无代谢活化。这些研究包括：（i）沙门氏菌和大肠杆菌突变（艾姆斯）试验，（ii）L5178Y小鼠淋巴瘤细胞中胸苷激酶基因座正向突变试验，（iii）中国仓鼠卵巢细胞染色体畸变试验，以及（iv）体内大鼠骨髓红细胞微核试验。在每项研究中，均没有证据表明DCA具有诱变活性。有可能目前这种药用级的测试材料比以前报告中研究的材料杂质更少。这些数据扩展了先前关于DCA的已发表报告，并且在某些情况下与之相矛盾。
